Hjem › Akut bifænotypisk leukæmi › Texas
Akut bifænotypisk leukæmi kliniske forsøg i Texas
13 studier for Akut bifænotypisk leukæmi søger deltagere på steder i Texas.
Byer i Texas
- Houston11 studier
- Dallas6 studier
- Fort Worth5 studier
- Austin3 studier
- San Antonio3 studier
- Corpus Christi3 studier
- El Paso3 studier
Officiel studietekst (engelsk)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 12 til 78 · Alle køn · Opdateret 29. sep. 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- og 7 flere
RekruttererFase 2
365 Days · Alle køn · Opdateret 25. sep. 2026 · NCT06317662Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT03683433Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- og 12 flere
RekruttererFase 3
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- og 10 flere
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- UT Southwestern/Simmons Cancer Center, Dallas
- Cook Children's Medical Center, Fort Worth
RekruttererFase 1
Alder 1 til 30 · Alle køn · Opdateret 3. aug. 2026 · NCT06177067Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 15 til 80 · Alle køn · Opdateret 30. jul. 2026 · NCT02727803A Study of Revumenib and Mezigdomide in People With Leukemia
- MD Anderson Cancer Center (Data Collection Only), Houston
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 22. jun. 2026 · NCT07356154Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 12. jun. 2026 · NCT04047641Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 20. maj 2026 · NCT02115295The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.